ReviewMolecules (Basel, Switzerland)2014
Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?
Review in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 216 citations in OpenAlex.
- Pooled it
- Resveratrol as a Bioactive Compound for Edible Fish Muscle Quality: Emerging Evidence, Putative Mechanisms, and Future Perspectives.Foods (Basel, Switzerland) · 2026Review
- Piceatannol as a safe senotherapeutic: ameliorating senescence-associated markers in a radiation-induced murine model.Cell death discovery · 2026Article
- Adenosine APharmaceuticals (Basel, Switzerland) · 2026Article
- Resveratrol therapy modulates inflammatory biomarkers and reverses mechanical allodynia in rats subjected to a temporomandibular joint arthritis model.Inflammopharmacology · 2026Article
- Natural Phytochemicals as Inhibitors of HIF-1α in Breast Cancer: Review of Preclinical Evidence and Future Prospects.Current issues in molecular biology · 2026Review
- The Multidirectional Biological Activity of Resveratrol: Molecular Mechanisms, Systemic Effects and Therapeutic Potential-A Review.Nutrients · 2026Review
- Multi-Omics and Molecular Simulation Identify KIF11 as a Candidate Direct Target of Resveratrol in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Targeting cancer hallmarks using resveratrol: isolation, formulation, and mechanisms of action.Frontiers in nutrition · 2026Review
- Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities.Oncology research · 2026Review
- Influence of Certain Natural Bioactive Compounds on Glycemic Control: A Narrative Review.Nutrients · 2025Review
- From Elixirs to Geroscience: A Historical and Molecular Perspective on Anti-Aging Medicine.Molecules (Basel, Switzerland) · 2025Review
- Effects of Short-Term Feeding of Resveratrol on Growth Performance, Meat Quality, Antioxidant Capacity, Serum Biochemical Parameters and Intestinal Health in Yellow-Feathered Broilers Under Dexamethasone-Induced Oxidative Stress.Antioxidants (Basel, Switzerland) · 2025Article
- Natural Products as Potential Therapeutic Candidates for Diabetic Kidney Disease: Molecular Mechanisms, Translational Challenges, and Future Prospects.International journal of molecular sciences · 2025Review
- In Vitro and In Vivo Effects of Resveratrol on Rat Hepatic CYP1A2.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Synergizing Virtual Screening and Zebrafish Models to Identify Resveratrol-Derived Antiaging Polyphenols.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The geroprotective potential of chalcones.Nature communications · 2025Review
- Resveratrol: potential therapeutic effects on ocular health.Inflammopharmacology · 2025Review
- Resveratrol as a Therapeutic Agent in Alzheimer's Disease: Evidence from Clinical Studies.Nutrients · 2025Review
- Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol has emerged as a leading candidate for improving healthspan through potentially slowing the aging process and preventing chronic diseases. The poor bioavailability of resveratrol in humans has been a major concern for translating basic science findings into clinical utility. Although a number of positive findings have emerged from human clinical trials, there remain many conflicting results, which may partially be attributed to the dosing protocols used. A number of theoretical solutions have been developed to improve the bioavailability of resveratrol, including consumption with various foods, micronized powders, combining it with additional phytochemicals, controlled release devices, and nanotechnological formulations. While laboratory models indicate these approaches all have potential to improve bioavailability of resveratrol and optimize its clinical utility, there is surprisingly very little data regarding the bioavailability of resveratrol in humans. If bioavailability is indeed a limitation in the clinical utility of resveratrol, there is a need to further explore methods to optimize bioavailability in humans. This review summarizes the current bioavailability data, focusing on data from humans, and provides suggested directions for future research in this realm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.